- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14:59 | Ipsen appoints Michelle Werner as North America head | ||
| 13:59 | Evotec slashes staff as turnaround plan gathers pace | ||
| 12:59 | Eisai joins with Pokémon for sleep awareness drive | ||
| 11:58 | NVIDIA sinks $2bn into AI cloud provider Nebius | ||
| Mi | Novo rapped by FDA for not reporting drug adverse effects | ||
| Mi | NHS cleared to use Astellas' non-hormonal menopause drug | ||
| Mi | Vertex preps FDA filing for IgAN drug after phase 3 readout | ||
| Mi | NICE says no to Genmab cervical cancer therapy | ||
| Mi | Veeva buys brand engagement firm Ostro for $100m | ||
| Di | FDA approves leucovorin - but not for autism | ||
| Di | FDA cuts testing requirements for biosimilars once again | ||
| Di | BioNTech bigwigs will step down to form new mRNA company | ||
| Di | Lundbeck names AI head in quest to become 'bionic' company | ||
| Di | BMS eyes another celmod filing in myeloma after phase 3 win | ||
| Mo | Novo partners with Hims & Hers again, ending GLP-1 spat | ||
| Mo | Incyte breaks new ground in anal cancer with EU approval | ||
| Mo | Alfasigma licenses liver drug from GSK in $590m deal | ||
| Mo | Roche's oral SERD flunks phase 3 breast cancer test | ||
| Mo | Safety concerns prompt Ipsen to pull Tazverik from market | ||
| Fr | Servier snaps up cancer biotech Day One in $2.5bn deal | ||
| Fr | Zealand Pharma hit as Roche-partnered obesity drug disappoints | ||
| Fr | Daiichi teams up with GAIA for cholesterol DTx in Europe | ||
| Fr | China's clears Pfizer GLP-1 ecnoglutide for weight loss | ||
| Fr | J&J's Tecvayli claims third national priority FDA approval | ||
| Fr | Alnylam bets on Tenaya RNAi tech, and other licensing news |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.